Molecular Templates, Inc. (MTEM)
Fuera de horario:
Molecular Templates, Inc.
9301 Amberglen Boulevard
Suite 100
Austin, TX 78729
United States
512 869 1555
https://www.mtem.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 62
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Eric E. Poma Ph.D. | CEO, Chief Scientific Officer & Director | 723.81k | N/D | 1972 |
| Ms. Jason S Kim | President, CFO, Treasurer & Principal Accounting Officer | 522.3k | N/D | 1975 |
| Ms. Kristen Quigley B.A. | Chief Operating Officer | N/D | N/D | 1971 |
| Dr. Grace Kim | Chief Strategy Officer & Head of IR | N/D | N/D | N/D |
| Dr. Michelle Iwamoto-Fan J.D., Ph.D. | Senior Vice President & General Counsel | N/D | N/D | N/D |
| Dr. Joseph Phillips Ph.D. | Senior VP & Head of CMC Development | N/D | N/D | N/D |
| Dr. Chris Moore Ph.D. | Senior VP and Head of Preclinical Development & Translational Medicine | N/D | N/D | N/D |
Descripción
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Gestión corporativa
La calificación ISS Governance QuickScore de Molecular Templates, Inc. a partir del 1 de mayo de 2024 es 7. Las puntuaciones principales son Auditoría: 9; Junta: 7; Derechos del accionista: 5; Compensación: 7.
